Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma

BACKGROUND: The clinical consequences of pancreatic exocrine insufficiency and its treatment in advanced pancreatic ductal adenocarcinoma (PDAC) are poorly investigated. This retrospective study aims at investigating the pancreatic enzyme replacement therapy (PERT) use and its impact on survival and...

Descripción completa

Detalles Bibliográficos
Autores principales: Trestini, Ilaria, Carbognin, Luisa, Peretti, Umberto, Sperduti, Isabella, Caldart, Alberto, Tregnago, Daniela, Avancini, Alice, Auriemma, Alessandra, Orsi, Giulia, Pilotto, Sara, Frulloni, Luca, Capurso, Gabriele, Bria, Emilio, Reni, Michele, Tortora, Giampaolo, Milella, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458827/
https://www.ncbi.nlm.nih.gov/pubmed/34568019
http://dx.doi.org/10.3389/fonc.2021.688889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458827/
https://www.ncbi.nlm.nih.gov/pubmed/34568019
http://dx.doi.org/10.3389/fonc.2021.688889

Ejemplares similares